Kadcyla (ado-trastuzumab emtansine) - 160 mg Vial For Injection
Object Details
- Genentech, Inc.
- Description (Brief)
- (From insert) KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either:
- --Received prior therapy for metastatic disease, or
- -- Developed disease rescurrence during or within six months of completing adjuvant therapy.
- Location
- Currently not on view
- Credit Line
- Gift of Genentech, Inc.
- ca 2013
- product expiration date
- 2015-11
- ID Number
- 2013.0069.06
- catalog number
- 2013.0069.06
- accession number
- 2013.0069
- Object Name
- pharmaceutical
- biological
- Physical Description
- plastic (overall material)
- glass (overall material)
- metal (overall material)
- cardboard (overall material)
- ado-trastuzumab emtansine, 160mg (overall ingredient)
- Measurements
- overall: 1 1/2 in x 2 3/4 in x 5 1/4 in; 3.81 cm x 6.985 cm x 13.335 cm
- bottle of kadcyla: 2 1/2 in x 1 1/4 in; 6.35 cm x 3.175 cm
- overall: 5 3/8 in x 2 3/4 in x 1 3/8 in; 13.6525 cm x 6.985 cm x 3.4925 cm
- place made
- United States: California, South San Francisco
- See more items in
- Medicine and Science: Medicine
- Health & Medicine
- The Antibody Initiative
- Antibody Initiative: Monoclonal Antibodies
- National Museum of American History
- Subject
- Women's Health
- Record ID
- nmah_1445167
- Metadata Usage (text)
- CC0
- GUID (Link to Original Record)
- https://n2t.net/ark:/65665/ng49ca746ad-d915-704b-e053-15f76fa0b4fa
Related Content
There are restrictions for re-using this image. For more information, visit the Smithsonian's Terms of Use page .
International media Interoperability Framework
IIIF provides researchers rich metadata and media viewing options for comparison of works across cultural heritage collections. Visit the IIIF page to learn more.